NIH Using PharmaJet in DNA Vaccine Clinical Trial
PharmaJet recently announced that the National Institutes of Health will use the PharmaJet Stratis needle-free device in a DNA vaccine clinical trial for the Zika virus.
DNA vaccines are the way of the future. Unlike traditional vaccines, like for flu or measles, that contain whole viruses, DNA vaccines contain just a tiny piece of a virus’s genetic code, making them safe and easy to work with. For these vaccines to work however, it is not enough to just get into the bloodstream like a traditional injection, the DNA vaccine must get directly into the cells. For that purpose, a new delivery method was needed.
“The PharmaJet needle-free device is ideal to deliver DNA vaccines, and we are collaborating with several partners in this development effort. The device uses a narrow stream of fluid that goes through the skin, directly into the cells, without a needle, in about 1/10th of a second. It offers a safe, fast, and easy-to-use method to deliver the vaccine,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc.
Based in Golden, CO, PharmaJet’s mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. PharmaJet’s devices are also integral in the development of multiple novel pharmaceuticals. The innovative Stratis device has US FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. In August 2014, the PharmaJet Stratis device was cleared for delivery of an influenza vaccine to deliver needle-free flu shots. The Tropis device for intradermal injections received authorization to apply the CE Mark in 2016. The PharmaJet needle-free devices are safe, fast, and easy-to-use. They eliminate needlestick injuries, needle reuse, and cross contamination, and help reduce sharps waste disposal. For more information, visit www.pharmajet.com.
Total Page Views: 1124
